Evidence map›Paper›PMID 41107652›Full record

ArticleClinical journal of gastroenterology2026

Managing dual primary liver metastases from breast and colorectal cancers.

Ryota Ito, Atsushi Oba, Takayuki Kobayashi, Keisuke Sugita, Manabu Takamatsu, Shota Fukuoka, Eiji Shinozaki, Satoshi Tsuchiya, Kiyoshi Matsueda, Kosuke Kobayashi and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ryota ItoDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Atsushi ObaDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan. atsushi.oba@jfcr.or.jp.ORCID http://orcid.org/0000-0002-7315-0830
Takayuki KobayashiBreast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Keisuke SugitaDepartment of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Manabu TakamatsuDepartment of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Shota FukuokaDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Eiji ShinozakiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Satoshi TsuchiyaDepartment of Diagnostic Ultrasound and Interventional Radiology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kiyoshi MatsuedaDepartment of Diagnostic Ultrasound and Interventional Radiology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kosuke KobayashiDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Yoshihiro OnoDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Hiromichi ItoDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Yosuke InoueDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Akio SaiuraDepartment of Hepatobiliary-Pancreatic Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Yu TakahashiDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the treatment of metastatic liver tumors, identifying the primary cancer is crucial for determining the appropriate treatment strategy. The management of colorectal liver metastases often centers around surgical resection, whereas breast cancer liver metastases are predominantly treated with chemotherapy. To our knowledge, this case represents a rare example of dual primary liver metastasis. CASE PRESENTATION: A 55-year-old female underwent systemic therapy with tamoxifen plus T-DM1 after right breast cancer resection 3 years ago. Two years ago, the patient developed simultaneous sigmoid colon cancer with liver metastasis. Due to liver damage from T-DM1, she initially underwent sigmoid colon resection, followed 2 months later by partial S5/8 resection and caudate lobectomy. S5/8 lesion was histologically diagnosed as colon cancer liver metastasis, while the caudate lobe lesion was breast cancer liver metastasis. 6 months after surgery, five liver metastases recurred, and the patient was diagnosed with liver metastatic recurrence of colorectal cancer. Six cycles of chemotherapy FOLFOX + Cetuximab were administered before surgery. The largest lesion of S5/8 shrunk, and the other four lesions were slightly enlarged. The histological examination confirmed the shrunken lesion as colorectal liver metastasis and the other lesions as breast cancer liver metastases.

conclusionAlthough radiological differentiation of metastatic liver lesions is challenging, chemotherapy response and tumor localization can aid in diagnosis. Multi-disciplinary cooperation is essential in determining treatment strategies for dual primary liver metastases.

Indexed as

Breast NeoplasmsColorectal NeoplasmsLiver NeoplasmsNeoplasms, Multiple PrimaryAntineoplastic Combined Chemotherapy ProtocolsFemaleFluorouracilHumansLeucovorinMiddle AgedOrganoplatinum CompoundsFluorouracilLeucovorinOrganoplatinum CompoundsBreast cancer metastasisColorectal liver metastasisDual primary liver metastasesLiver impairmentSinusoidal obstructive syndromeT-DM1Trastuzumab emtansine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.